

A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on **Wednesday, 23rd March 2022 via Microsoft Teams MINUTE**

Present: Chair - Alison Wilson (Director of Pharmacy) (AW); Liz Leitch, Formulary Pharmacist; Dr Nicola Henderson, GP (NH); Keith Allan, Public Health Consultant; Adrian Mackenzie, Lead Pharmacist Community Pharmacy (AMack); Rhona Morrison, Medicines Governance Lead (RM); Dr Effie Dearden, DME Consultant (ED); Dr Ed James, Consultant (EJ); Keith Maclure, Lead Pharmacist Medicines Utilisation (KMacl); Kate Warner, Minute Taker (KW)

Guests: Claire Irvine (Macmillan Lung Nurse Specialist, Macmillan Centre)

Item	Situation ; Background; Assessment	Recommendation	Person	Timescale
1.	Apologies and Announcements: Andrew Leitch, Lay-Member			
2.	Declarations of Interest: None			
3.	DRAFT Minute previous meeting			
3.1	Draft minute from 26 th January 2022 meeting was approved as an accurate record of the	Publish minute	KW	24/03/2022
	meeting with no changes.			
4.	Matters Arising			
4.1	ADTC discussed Thyroid Armour; previously discussed at January ADTC - minute in NFR		LL/KW	30/03/2022
	subfolder. ADTC discussed the non-formulary request form and agreed that there should be	include if treatment		
	additional section on the NFR form for NFR which are for on-going prescribing rather than for	is on-going		
	initiation of prescribing, ADTC also discussed that with ERF we may have patients who whose	prescribing.		
	treatment will become non-formulary and there needs to be a process to manage.			
4.2	Community Hospital Discharge Medicines Management Policy; previously reviewed and	ADTC noted this		
	updated. Approved by Pharmacy Contractors Committee; flowchart changed on page 3 to			
	ensure discharge letter goes to community pharmacy at earliest opportunity. KMacl meeting		KMacl	31/03/2022
	with RM to discuss and finalise the measures and outcomes expected from the pilot. Nurses			
	have reviewed the discharge policy and a stakeholder meeting is planned for next week to	benefits in final		

	ensure that all are aware of policy.	policy.		
4.3	NHS Borders Symptomatic Relief Policy – changes requested in July 2021 updated by Kyna			
1 .5	Harvey Mental Health Pharmacist and re-submitted for approval.	Email to KH and	KW	28/03/2022
	Harvey Mental Health Frialmacist and re-submitted for approval.	upload to intranet	rxvv	20/03/2022
5.	NEW MEDICINE APPLICATIONS / NON FORMULARY REQUESTS:	upload to intraffet		
5.1	NFR Pyridostigmine – discussed by ADTC; minute and decision letter in NFR subfolder.	Letter to applicant	KW	28/03/2022
5.2	NFR Ostenil Plus – discussed by ADTC; minute and decision letter in NFR subfolder.	Letter to applicant	KW	28/03/2022
5.3	Update to NFR form In discussions above ADTC agreed that the Non Formulary Request form	Update NFR form	LL/KW	30/03/2022
5.5	should be updated to include if the patient is established on the treatment, for how long,	and republish to	LL/KVV	30/03/2022
	benefits and how benefits will be measured.	Intranet		
6.	PATIENT & MEDICINES SAFETY:	IIIIIaiiei		
0.	Datix Review – RM reported more recent errors on CDs and in April will be visiting all clinical	ADTC Noted	1	
6.1	areas to audit practice; since cabinet installation there are not the previous daily CD checks at	ADTO Noted		
0.1	shift handover. Visits to be over coming months.			
7.	CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL:			
7.1	NHS Borders Thematic Review of Medication Errors December 2020 – December 2021	ADTC Noted	1	
7.1			KW/RM	15/06/2022
	includes Acute and P&CS with a total of 590 errors reported. Similar numbers for BGH and Primary Care. Some figures skewed by events which were discussed; insulin errors have been		KVV/KIVI	15/06/2022
	reduced as a result on on-going education. A review of what is reported will be made to ensure			
	grading is comparable. Missed medications are included in errors and this is being reviewed on			
	Surgical floor and DME. Largest error in community was vaccinations which were attributed to		LL/RM	30/04/2022
			AW	07/04/2022
	incorrect vaccine given to patients for their criteria at start of Covid. RM will be working on data		AVV	07/04/2022
	for 2019/20/21 for future reviews in other areas. LL commented that all Anticoagulation Datix	behalf of ADTC		
	are reviewed by the Anticoagulation Committee and for areas of concern, Dr Paul Neary has	behall of ADTC		
	offered to deliver teaching to ward staff. CD errors remain a concern and LL commented on the			
	Omnicell miscounting accounting for errors regarding CDs. Ward 4 would welcome support on			
	this; RM to contact SCN Ward 4 to discuss. ED asked ADTC to consider that most wards are			
	running with lower nursing staff levels than previously considered safe and nurses are also			
	working in unfamiliar areas – this should be flagged to NHS Borders Board – as errors happen			
	in a stressed system. ADTC agreed that this should be raised and discussed further. AW			
	informed that the Thematic Review will be included in the Pharmacy Annual Report which goes			
	to Clinical Governance Committee in September and then onto the Board as a method of			
	reporting. RM will review bed state and specific spikes that coincide with ward changes. RM			
	spoke of the Anticoagulation teaching sessions; AW asked if a Clinical Development Fellow			
	could be involved in audit work to look at incidents and knowledge before/after - RM and LL			
	agreed to discuss separately along with missed medication review work being done in ward 7			
	and 9.			

7.2	ADTC discussed NHS Borders procedure for Non-Formulary Request (NFR) approvals,	ADTC Approved		
1.2	previously approved by Borders Formulary Committee and not being reviewed by East Region			
	Formulary. NFRs will continue to be reviewed within each Board. Way this is done in other		KW	28/03/2022
	Boards was discussed as well as the options listed in SBAR. AW asked that, in first bullet			
	"approved" be "decision taken"; ADTC agreed that there should be shared responsibility for		LL	28/03/2022
	decisions and that a regular half hour Teams meeting (perhaps in place of previous BFC	membership to KW		
	meeting) could be utilised for discussion and cancelled if no applications to discuss. Where			
	urgent the discussion can be done by email – but ADTC stressed that these must be clinically			
	urgent for this to happen.			
7.3	ADTC discussed NHS Lothian flowchart and agreed to continue using current NHS Borders	Update; LL to check;	KW	30/04/2022
7.4	flowchart with any new process/forms for new medicines applications.	update on intranet		
7.4	Abbreviated Borders Joint Formulary – updated with the changes from Borders to East Region	ADTC Approved Format to be	KW	20/04/2022
	Formulary and reduced in size. Some changes were highlighted and these are included in the update information shared with prescribers. Plan is to change this format to be similar to the	updated and shared	I NVV	30/04/2022
	Empirical Antimicrobial Guidelines chart; this will be laminated for the wards and also shared	upuateu anu shareu		
	with all prescribers, including NMPs, by email/Teams groups and intranet.			
7.5	ADTC Terms of Reference – updated with Groups/Committees that would previously have	ADTC approved		
	reported to Borders Formulary Committee and now report to ADTC.			
8.	FOR INFORMATION and NOTING:			
8.1	East Region Formulary updates 1 ERF Committee minute – 2 nd February 2022; 2 ERWG	ADTC Noted		
	minute – 9 th March 2022; 3 Progress on ERF prescribing.			
8.2	Changes from Borders Joint Formulary to East Regional Formulary	ADTC Noted		
8.3	NHS Lothian Unlicensed Medicines Procedure – peer reviewed, Lothian ADTC approved and	ADTC Noted		
	can be found at Safe Use of Medicines Policy link			
8.4	Methylcellulose substitute has been raised at ERFC; a formulary application is in progress.	ADTC Noted		
8.5	DVT Ambulatory Care Pathway – uploaded to Clinical Area and subsequent link to other microsites.	ADTC Noted		
8.6	Updated guidance - Parkinson's Disease - no changes; uploaded to Clinical Area	ADTC Noted		
8.7	Sapropterin update- email from HIS	ADTC Noted		
9.	FEEDBACK from SUB GROUPS			
9.1	Anticoagulation Committee – no recent meeting.			
9.2	Antimicrobial Management Team – February meeting; minute not available.			
9.3	Controlled Drug Governance Team – no recent meeting.			
9.4	IV Therapy Group – DRAFT 9 th March 2022	MRG Noted		
9.5	Medicines Resource Group – DRAFT – 26 th January 2022	MRG Noted		
9.6	Non-Medical Prescribing Group – no recent meeting.			
	·		•	•

9.7	Tissue Viability Steering Group – no recent meeting.				
9.8	Wound Formulary Group – no recent meeting.				
9.9	NHS Lothian ADTC – DRAFT 3 rd December 2021	MRG Noted			
10.	AOCB				
10.1	None				
Date and time of next meeting: Wednesday 25 th May 2022 at 12:30pm via Microsoft Teams.					

Items for May 2022 meeting: